Ongoing Assessments & Recent Research.
Easy access to our work
Multiple Sclerosis: SPMS
Jun 2025Non-Cystic Fibrosis Bronchiectasis
Sep 2025Obesity Management
Nov 2025Retinitis Pigmentosa
Apr 2025Spinal Muscular Atrophy
Aug 2025Featured News & Insights.
Learn about our latest work.
Institute for Clinical and Economic Review to Assess Treatments for Obesity Management
Report will be subject of New England CEPAC meeting in November 2025; Draft Scoping Document open to public comment until May 19, 2025.
04/29/2025Institute for Clinical and Economic Review Releases Draft Evidence Report on Treatment for Secondary Progressive Multiple Sclerosis
Public comment period now open until May 13, 2025; Requests to make oral comment during public meeting also being accepted.
04/15/2025Institute for Clinical and Economic Review Releases Obesity Medications White Paper Examining Strategies to Ensure Affordable Access
Paper analyzes policy reforms and market actions to achieve affordable and equitable access for GLP-1 obesity medications; developed as part of ICER’s Policy Leadership Forum with input from diverse stakeholders.
04/09/2025Our Origin Story.
Dr. Steve Pearson explains why he founded an organization to advance the use of evidence to improve health care affordability and access for all patients and their families.
The ICER Impact.
New York Medicaid pursued discounts, many of which were in line with ICER reports, which have saved the state over $500 million
Engaged with over 400 patient groups and patient reps
The ICER-developed Clinical trial Diversity Rating (CDR) Tool presents a framework for evaluating the demographic diversity of clinical trial populations in a consistent, transparent manner leading to an overall diversity rating. Learn more.
Current
Policy Papers.
Easy access to our latest policy papers
Special Report on COPD Therapies as Part of CMS Public Comment Process on Medicare Drug Price Negotiations
ICER developed a special report for CMS on two therapies in high demand for treating chronic obstructive pulmonary disease (COPD). This report was submitted to CMS as part of the 2025 public comment process defined in CMS guidance on Medicare Drug Price Negotiations for price applicability year 2027.
Examining Strategies to Ensure Affordable Access for Obesity Medications
ICER, in collaboration with researchers from Brown University, published a new white paper that provides clear policy and market solutions to help manage affordable and equitable access to GLP-1 obesity medications.
The paper seeks to present insights and lessons learned from experts, while offering a menu of options that will help all stakeholders play an active part in an innovative future of pricing, coverage, and payment for new obesity medications.
Unsupported Price Increases
Of 10 high-expenditure drugs that had substantial 2023 net price increases, five were not supported by new clinical evidence; these increases accounted for $815 million in additional costs in 2023.The five drugs with unsupported price increases are Biktarvy, Darzalex, Entresto, Cabometyx, and Xeljanz.